Clinical Assessment of the Treatment With Cardiac Sympathetic Blockade on Chronic Heart Failure
NCT ID: NCT02391142
Last Updated: 2018-08-08
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
UNKNOWN
NA
100 participants
INTERVENTIONAL
2014-06-30
2019-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Effects of Cardiac Sympathetic Blockade in Patients With Chronic Heart Failure
NCT02282618
Effect of NT-proBNP Guided Treatment of Chronic Heart Failure
NCT00149422
The Influence of Beta Blocker Therapy on the Hemodynamic Response to Inotrope Infusion in Patients With Acute Decompensated Heart Failure
NCT01971944
Cardiac Denervation Ablation Strategy for Severe Sinus Bradycardia
NCT06276816
The Nitrite and Coronary Flow Study
NCT04354051
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
cardiac sympathetic nerve block
lidocaine or ropivacaine epidural injection
Lidocaine
0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks
non-cardiac sympathetic nerve block
No interventions assigned to this group
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Lidocaine
0.5% lidocaine 5ml epidural injection every 2 hours per day or 0.2% ropivacaine 5ml epidural injection every 4 hours per day, last for 4weeks
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* more than 3 months of chronic heart failure history or clinical symptoms of heart failure last for more than 3 months (including acute episode of chronic heart failure), chronic heart failure diagnostic criteria refer to 2012ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure
* NYHA functional class III-IV, ejection fraction ≤45%
* NT-proBNP\>400ng/L
Exclusion Criteria
* unrepaired valvular heart disease accompanied with Hemodynamic changes
* hypertrophic cardiomyopathy, pericardial disease, congenital heart disease, severe pulmonary hypertension
* Second-degree type 2 or worse sinoatrial or atrioventricular block without pacemaker therapy
* right heart failure caused by various diseases, respiratory failure or right heart failure induced by chronic obstructive pulmonary disease
* overt renal decompensation: serum creatinine\>2.1mg/dl(186umol/L)
* severe hepatic dysfunction, transaminase or alkaline phosphatase \> 3 times the upper limit of normal
* Cerebral vascular accident in three months( cerebral infarction, cerebral embolism, cerebral hemorrhage,etc)
* life expectancy shorter than 6 months
* patients with a previous or present history of tumour or precancerous lesions confirmed by pathological examination
* Spine Deformity or skin infection at puncture site
* participate in any clinical drug trials in the three months
* the patients who do not sign the informed consent, unable or unwilling to comply with the requirements of the protocol or unsuitable for the study
20 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
First Affiliated Hospital of Harbin Medical University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
the First Affiliated Hospital of Harbin Medical University
Harbin, Heilongjiang, China
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
CSB-CHF
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.